


CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:

Date: July 14, 2009 Name: Heidi A. Dare, Reg. No. 50,775 Signature: 

**Attorney Docket No. 8465-40
Client Reference No. P200101243 US2**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Lasse W. Mogensen et al.

Appln. No.: 10/687,568

Examiner: Elizabeth Rose Moulton

Filed: October 15, 2003

Group Art Unit: 3767

For: INJECTOR DEVICE FOR PLACING
A SUBCUTANEOUS INFUSION SET

Confirmation No.: 7139

Attorney Docket No: 8465-40

NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop AF
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 CFR§1.56 and§ 1.97-1.98, and more particularly in accordance with 37 CFR §1.97(d), Applicants hereby cite the following references:

FOREIGN PATENT DOCUMENTS		
DOCUMENT NO.	DATE	COUNTRY
EP 0 799 626 A1	10/1997	Europe
JP 10-15075 A	01/1998	Japan
WO 99/33504	07/1999	WIPO

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Japanese Office Action mailed June 15, 2009 for Japanese Patent Application No. 2003-530539, with English translation.

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 CFR§1.98(a)(2). EP 0 799 626 A1 is believed to be the English language equivalent of JP 10-15075 A. An English translation of the Japanese Office Action mailed June 15, 2009 for JP 2003-530539 is provided. Applicants respectfully request the Examiner's consideration of the above references and entry thereof into the record of this application.

By submitting this Statement, Applicants are attempting to fully comply with the duty of candor and good faith mandated by 37 CFR§1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 CFR§1.56(a).

For purposes of 37 CFR §1.704(d), the Applicants certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 CFR§1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement (a copy of any foreign communication first citing a listed reference is attached for the Examiner's reference).

Applicants certifies under 37 CFR§1.97(e)(1) that each item of information in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (a copy of any foreign communication first citing a listed reference is attached for the Examiner's reference). Applicants have further calculated a processing fee in the amount of \$180.00 to be due under 37 CFR

§1.17(p) in connection with the filing of this Information Disclosure Statement. Applicants have authorized charging the fee to a deposit account, as indicated in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

July 14, 2009

Date


Heidi A. Dare
(Reg. No. 50,775)